Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cagrilintide/semaglutide - Novo Nordisk

Next Previous
Drug Profile

Cagrilintide/semaglutide - Novo Nordisk

Alternative Names: CagriSema; NN-9388; Semaglutide/Cagrilintide - Novo Nordisk

Latest Information Update: 15 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novo Nordisk
  • Class Antihyperglycaemics; Glucagon-like peptides; Hepatoprotectants; Obesity therapies; Urologics; Vascular disorder therapies
  • Mechanism of Action Amylin receptor agonists; Glucagon-like peptide-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Obesity
  • Phase III Type 2 diabetes mellitus
  • Phase II Alcoholic liver disorders; Diabetic neuropathies

Most Recent Events

  • 04 May 2026 Novo Nordisk plans a phase III trial for Obesity in Argentina, Australia, Austria, Belgium, Bulgaria, Canada, Czechia, France, Greece, Hungary, Italy, Netherlands, Poland, Portugal, Romania, Slovakia, South Africa, Spain, the US, in May 2025 (SC) (NCT07564414)
  • 22 Apr 2026 Novo Nordisk completes a phase III trial for Obesity in United Kingdom, USA, Canada, France and Germany (SC) (NCT06388187)
  • 06 Mar 2026 Novo Nordisk plans a phase I/II trial for Obesity in Denmark (CTIS2025-522920-28-00)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top